Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology 2024-02-21 22:00
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics 2024-02-21 18:00
Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA 2024-02-21 12:26
Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine 2024-02-21 09:00
Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology 2024-02-20 22:30
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711 2024-02-20 22:00
FDA Grants Orphan Drug Designation to 9MW3011 2024-02-20 22:00
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma 2024-02-20 21:00
Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress) 2024-02-20 20:00
Origin Agritech Regains Compliance with Nasdaq Listing Standards 2024-02-20 20:00
HKUST Neuroscientists Develop Highly Accurate Universal Diagnostic Blood Test for Alzheimer's Disease and Mild Cognitive Impairment 2024-02-19 20:18
Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S. 2024-02-19 19:30
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis 2024-02-19 09:00
Everest Medicines Announces Termination of Collaboration Agreements with Providence 2024-02-19 08:20
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor 2024-02-18 20:50
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC 2024-02-16 22:03
Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED. 2024-02-15 17:05
Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis 2024-02-15 16:05
iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology 2024-02-15 11:37
YS Biopharma Announces Appointment of New Directors 2024-02-14 20:50
1 15 16 17 18 19 415